Personalis, Inc. (PSNL)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry. Technicals were still computed and the chart itself is constructive, but the override gate blocks a trade.
Company overview
Personalis, Inc. is a cancer genomics company providing advanced sequencing and data analysis solutions. Their NeXT Platform supports tumor and immune microenvironment analysis, offering products like ImmunoID Next and NeXT Liquid Biopsy. The company serves biopharmaceutical firms, academic institutions, and government entities.
Fundamental
weakPersonalis faces liquidity challenges with significant losses and declining revenue, despite a strong cash position.
Personalis is liquid but still heavily loss-making: Q1 2026 liquidity totals about $233M (cash + short-term investments) and the current ratio is ~6.6, yet cash burn and losses remain large (FY2025 operating cash flow about -$75M; TTM net margin ~-148%). Revenue contracted in FY2025 (≈$69.6M, derived from quarterly results) and Q1 2026 revenue fell ~25% YoY. With EV/Sales around 16.6x and negative free-cash-flow yield (~-7.6%), the market is pricing in a major growth/coverage-driven turnaround that is not yet evident. SEC filings highlight customer concentration and regulatory/reimbursement uncertainty; an 8-K disclosed expanded Medicare coverage for NeXT Personal as a potential catalyst. Fundamental score: 2/5.
Sentiment
fairMedia coverage is slightly positive, but no clear short-term catalysts are identified.
Recent narrative remains supported by Medicare coverage expansion headlines and the 2026-06-09 CE‑IVD kit-marking milestone, but we found no clearly actionable 1–30 trading-day catalyst under the pipeline rules. Media sentiment over the last ~14d is mildly positive yet cooler than the bullish 30–90d baseline; legal screen is clean and Reddit sentiment is indeterminate due to repeated 429 rate limits.
Technical
goodTechnicals indicate strength with positive momentum, though the setup is not actionable due to fundamental constraints.
Chart quality is 4/5 because PSNL is above every major average and daily VWAP, MACD is positive above signal, ADX confirms a strong trend, and 20-day dollar volume easily clears the liquidity floor. I stop short of a 5 because RSI and Williams %R are overbought and SMA50 remains marginally below SMA200, so the move is powerful but extended. The action stays Do Nothing because fundamentalScore is 2, below the hard minimum of 3.
You’re looking at 2026-06-25 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.